Dolphin Medical Services (BOM:526504) EBITDA per Share: ₹0.11 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:526504 Dolphin Medical Services Ltd BOM:526504
36 GF Score
Price ₹8.24
GF Value ₹2.39
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Dolphin Medical Services EBITDA per Share?

Dolphin Medical Services BOM:526504 36 EBITDA per Share is ₹0.11 as of Mar. 2026. GuruFocus rates BOM:526504 with a GF Score™ of 36/100 and a GF Value™ of ₹2.39 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Dolphin Medical Services ranks worse than 598801.8% on this metric.

Dolphin Medical Services's EBITDA per Share for the three months ended in Mar. 2026 was ₹0.02. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.11.

During the past 12 months, the average EBITDA per Share Growth Rate of Dolphin Medical Services was 328.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Dolphin Medical Services's EBITDA per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Dolphin Medical Services was 48.90% per year. The lowest was -14.10% per year. And the median was 43.50% per year.

BOM:526504's 3-Year EBITDA Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 11
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Dolphin Medical Services's EBITDA for the three months ended in Mar. 2026 was ₹0.33 Mil.

During the past 12 months, the average EBITDA Growth Rate of Dolphin Medical Services was 285.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Dolphin Medical Services was 48.80% per year. The lowest was -14.10% per year. And the median was 43.40% per year.


Dolphin Medical Services  (BOM:526504) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Dolphin Medical Services EBITDA per Share Related Terms


Dolphin Medical Services EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Dolphin Medical Services's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dolphin Medical Services EBITDA per Share Chart

Dolphin Medical Services Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.03 -0.03 0.03 0.11

Dolphin Medical Services Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 0.03 0.03 0.03 0.02
BOM:526504
36GF Score
Dolphin Medical Services Ltd BOM:526504
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dolphin Medical Services EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Dolphin Medical Services's EBITDA per Share for the fiscal year that ended in Mar. 2026 is calculated as

EBITDA per Share(A: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=1.61/15.100
=0.11

Dolphin Medical Services's EBITDA per Share for the quarter that ended in Mar. 2026 is calculated as

EBITDA per Share(Q: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=0.329/15.100
=0.02

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of ₹0.11 mean?
Dolphin Medical Services (BOM:526504) has a EBITDA per Share of ₹0.11 as of Mar. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Dolphin Medical Services and its competitors. According to the industry distribution chart, Dolphin Medical Services ranks #999999 out of 167 companies in the Medical Diagnostics & Research industry.
Is Dolphin Medical Services' EBITDA per Share too high?
Dolphin Medical Services' current EBITDA per Share is ₹0.11. Based on the distribution chart, Dolphin Medical Services ranks #999999 out of 167 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Dolphin Medical Services has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dolphin Medical Services' EBITDA per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dolphin Medical Services ranks #999999 out of 167 companies for EBITDA per Share. This places Dolphin Medical Services in the lower half of its industry. The industry median EBITDA per Share is 11.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Medical Diagnostics & Research company?
The median EBITDA per Share among Medical Diagnostics & Research companies is 11.00, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Dolphin Medical Services and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA per Share is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dolphin Medical Services's current EBITDA per Share is ₹0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dolphin Medical Services stock overvalued right now?
Based on GuruFocus' analysis, Dolphin Medical Services (BOM:526504) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.39, compared to a current price of ₹8.24 — trading 244.8% above its estimated fair value. The current EBITDA per Share is ₹0.11. Dolphin Medical Services' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Dolphin Medical Services (BOM:526504), the current EBITDA per Share is ₹0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dolphin Medical Services (BOM:526504) Overvalued in 2026?

Based on GuruFocus' analysis, Dolphin Medical Services stock appears to be overvalued. The current stock price of ₹8.24 is trading 244.8% above its estimated GF Value™ of ₹2.39. GuruFocus considers Dolphin Medical Services to be Significantly Overvalued.

Key valuation signals for BOM:526504:

  • EBITDA per Share: ₹0.11
  • GF Value™: ₹2.39 vs. price of ₹8.24 (244.8% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the BOM:526504 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dolphin Medical Services Business Description

Address Kovelamudivari Veedhi, D.No.29-28/1-27, Suryaraopet, Vijayawada, AP, IND, 520002
Dolphin Medical Services Ltd is engaged in providing diagnostics and other allied services. It includes a range of tests covering radiology and imaging, biochemistry, pathology, and microbiology. In addition, the company is also involved in Information Technology, Biotechnology, and Herbal sectors. Services provided by the company are Diagnostic Centre provides all the services under one roof; the Ophthalmic Laser Care Centre provides total laser eye treatment as "Dolphin Nethralaya"; Teleradiology Services; Clinical Trials and Life Sciences division; Medical Equipment & Goods associated distribution; Bio-Tech Division is to provide Foods and Herbal Products and Dolphin Electronic Solution and Technologies(DEST).
36GF Score

Get the complete analysis for BOM:526504

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8.24
Price
₹2.39
GF Value